Related Experiment Video
Updated: Feb 15, 2026

Transient Expression in Red Beet of a Biopharmaceutical Candidate Vaccine for Type-1 Diabetes
Published on: March 19, 2019
Plants as bioreactors for biopharmaceuticals: regulatory considerations
1Division of Monoclonal Antibodies, Department of Health and Human Services, Food and Drug Administration, Bethesda, MD 20892, USA. miele@a1.cber.fda.gov
Abstract:
Plants are one of several novel hosts that can be used for the production of recombinant biopharmaceuticals such as cytokines, hormones, monoclonal antibodies, enzymes and vaccines. The novelty of this technology and its wide range of potential applications require an assessment of possible regulatory concerns in the clinical development of plant-derived biopharmaceuticals. General principles extrapolated from experience gained with biotechnology products from other sources can serve as a foundation to develop scientifically sound strategies for the large-scale production and clinical development of safe and effective biopharmaceuticals in plant hosts.
Related Concept Videos
Cis-regulatory Sequences
Cis-regulatory Sequences
Biopharmaceutics and Pharmacokinetics: Overview
Design Consideration
The factor of safety is another key...
Plant Hormones
Tensile Strength Considerations of Concrete
The dimensions and shape of a concrete specimen...

